Managing Joint Pain in Primary Care
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Inflammatory Back Pain in Patients Treated with Isotretinoin Although 3 NSAID Were Administered, Her Complaints Did Not Improve
Inflammatory Back Pain in Patients Treated with Isotretinoin Although 3 NSAID were administered, her complaints did not improve. She discontinued isotretinoin in the third month. Over 20 days her com- To the Editor: plaints gradually resolved. Despite the positive effects of isotretinoin on a number of cancers and In the literature, there are reports of different mechanisms and path- severe skin conditions, several disorders of the musculoskeletal system ways indicating that isotretinoin causes immune dysfunction and leads to have been reported in patients who are treated with it. Reactive seronega- arthritis and vasculitis. Because of its detergent-like effects, isotretinoin tive arthritis and sacroiliitis are very rare side effects1,2,3. We describe 4 induces some alterations in the lysosomal membrane structure of the cells, cases of inflammatory back pain without sacroiliitis after a month of and this predisposes to a degeneration process in the synovial cells. It is isotretinoin therapy. We observed that after termination of the isotretinoin thought that isotretinoin treatment may render cells vulnerable to mild trau- therapy, patients’ complaints completely resolved. mas that normally would not cause injury4. Musculoskeletal system side effects reported from isotretinoin treat- Activation of an infection trigger by isotretinoin therapy is complicat- ment include skeletal hyperostosis, calcification of tendons and ligaments, ed5. According to the Naranjo Probability Scale, there is a potential rela- premature epiphyseal closure, decreases in bone mineral density, back tionship between isotretinoin therapy and bilateral sacroiliitis6. It is thought pain, myalgia and arthralgia, transient pain in the chest, arthritis, tendonitis, that patients who are HLA-B27-positive could be more prone to develop- other types of bone abnormalities, elevations of creatine phosphokinase, ing sacroiliitis and back pain after treatment with isotretinoin, or that and rare reports of rhabdomyolysis. -
Synovial Fluidfluid 11
LWBK461-c11_p253-262.qxd 11/18/09 6:04 PM Page 253 Aptara Inc CHAPTER SynovialSynovial FluidFluid 11 Key Terms ANTINUCLEAR ANTIBODY ARTHROCENTESIS BULGE TEST CRYSTAL-INDUCED ARTHRITIS GROUND PEPPER HYALURONATE MUCIN OCHRONOTIC SHARDS RHEUMATOID ARTHRITIS (RA) RHEUMATOID FACTOR (RF) RICE BODIES ROPE’S TEST SEPTIC ARTHRITIS Learning Objectives SYNOVIAL SYSTEMIC LUPUS ERYTHEMATOSUS 1. Define synovial. VISCOSITY 2. Describe the formation and function of synovial fluid. 3. Explain the collection and handling of synovial fluid. 4. Describe the appearance of normal and abnormal synovial fluids. 5. Correlate the appearance of synovial fluid with possible cause. 6. Interpret laboratory tests on synovial fluid. 7. Suggest further testing for synovial fluid, based on preliminary results. 8. List the four classes or categories of joint disease. 9. Correlate synovial fluid analyses with their representative disease classification. 253 LWBK461-c11_p253-262.qxd 11/18/09 6:04 PM Page 254 Aptara Inc 254 Graff’s Textbook of Routine Urinalysis and Body Fluids oint fluid is called synovial fluid because of its resem- blance to egg white. It is a viscous, mucinous substance Jthat lubricates most joints. Analysis of synovial fluid is important in the diagnosis of joint disease. Aspiration of joint fluid is indicated for any patient with a joint effusion or inflamed joints. Aspiration of asymptomatic joints is beneficial for patients with gout and pseudogout as these fluids may still contain crystals.1 Evaluation of physical, chemical, and microscopic characteristics of synovial fluid comprise routine analysis. This chapter includes an overview of the composition and function of synovial fluid, and laboratory procedures and their interpretations. -
Clinical Data Mining Reveals Analgesic Effects of Lapatinib in Cancer Patients
www.nature.com/scientificreports OPEN Clinical data mining reveals analgesic efects of lapatinib in cancer patients Shuo Zhou1,2, Fang Zheng1,2* & Chang‑Guo Zhan1,2* Microsomal prostaglandin E2 synthase 1 (mPGES‑1) is recognized as a promising target for a next generation of anti‑infammatory drugs that are not expected to have the side efects of currently available anti‑infammatory drugs. Lapatinib, an FDA‑approved drug for cancer treatment, has recently been identifed as an mPGES‑1 inhibitor. But the efcacy of lapatinib as an analgesic remains to be evaluated. In the present clinical data mining (CDM) study, we have collected and analyzed all lapatinib‑related clinical data retrieved from clinicaltrials.gov. Our CDM utilized a meta‑analysis protocol, but the clinical data analyzed were not limited to the primary and secondary outcomes of clinical trials, unlike conventional meta‑analyses. All the pain‑related data were used to determine the numbers and odd ratios (ORs) of various forms of pain in cancer patients with lapatinib treatment. The ORs, 95% confdence intervals, and P values for the diferences in pain were calculated and the heterogeneous data across the trials were evaluated. For all forms of pain analyzed, the patients received lapatinib treatment have a reduced occurrence (OR 0.79; CI 0.70–0.89; P = 0.0002 for the overall efect). According to our CDM results, available clinical data for 12,765 patients enrolled in 20 randomized clinical trials indicate that lapatinib therapy is associated with a signifcant reduction in various forms of pain, including musculoskeletal pain, bone pain, headache, arthralgia, and pain in extremity, in cancer patients. -
Polyarthralgia: Joint Pain & Fibromyalgia
Polyarthralgia: Joint Pain & Fibromyalgia - Disabled World 07/23/2015 Skip to Content Accessibility HOME Disability ▼ Health ▼ Sports ▼ Products Videos ▼ About: Document Information A B C D E F G H I J K L M N O P Q • Author: Ian Langtree R S T U V W Y • Contact: Disabled World ★ Polyarthralgia: Joint Pain & Fibromyalgia • Published: 2009-04-22 (Revised: 2015-06-01) ▶ Health and Disability ▶ Bones & Joints - Conditions • Related Topics • Definition of Polyarthralgia Brief Synopsis: Information and • Cite This Document definition of Polyarthralgia usually used 3 Foods Cause Joint Pains to describe aches and pain affecting five • Add or Read Comments or more joints. medixselect.com • Print Page & Screen Readers The One Thing You Should Eat For Your Joints "Polyarthralgia is more common in Every Morning. -Video ▼ Awareness: Ribbons & Dates women and even more so with increasing age." 1 Trick to Fibromyalgia What is Polyarthralgia? Free Knee Pain Relief Kit • Awareness Ribbon Colors & Meaning Polyarthralgia is defined as aches in the • Awareness Days, Weeks & Months joints, joint pains, arthralgia of multiple Anterior Hip Replacement Today 07-23-2015 is: joints, and multiple joint pain. • World Sjogren's Day - Commemorates the Polyarthritis is the word usually used to describe pain affecting five or more joints, while a birthday of Henrik Sjogren, who first identified patient with 2 to 4 joints involved would be said to have oligoarticular disease. this disease in 1933, while bringing organizations across the world together to raise Polyarthralgia is more common in women and even more so with increasing age. awareness about Sjogren's. Polyarthralgia: Signs and Symptoms The initial symptoms, which usually appear in the third to fifth decade of life, include painless swelling or thickening of the skin of the hands and fingers, pain and stiffness of the joints Adrenal Fatigue (polyarthralgia), often mistaken for rheumatoid arthritis, and paroxysmal blanching and MDs cyanosis (becoming blue) of the fingers induced by exposure to cold (Raynaud syndrome). -
Approach to Polyarthritis for the Primary Care Physician
24 Osteopathic Family Physician (2018) 24 - 31 Osteopathic Family Physician | Volume 10, No. 5 | September / October, 2018 REVIEW ARTICLE Approach to Polyarthritis for the Primary Care Physician Arielle Freilich, DO, PGY2 & Helaine Larsen, DO Good Samaritan Hospital Medical Center, West Islip, New York KEYWORDS: Complaints of joint pain are commonly seen in clinical practice. Primary care physicians are frequently the frst practitioners to work up these complaints. Polyarthritis can be seen in a multitude of diseases. It Polyarthritis can be a challenging diagnostic process. In this article, we review the approach to diagnosing polyarthritis Synovitis joint pain in the primary care setting. Starting with history and physical, we outline the defning characteristics of various causes of arthralgia. We discuss the use of certain laboratory studies including Joint Pain sedimentation rate, antinuclear antibody, and rheumatoid factor. Aspiration of synovial fuid is often required for diagnosis, and we discuss the interpretation of possible results. Primary care physicians can Rheumatic Disease initiate the evaluation of polyarthralgia, and this article outlines a diagnostic approach. Rheumatology INTRODUCTION PATIENT HISTORY Polyarticular joint pain is a common complaint seen Although laboratory studies can shed much light on a possible diagnosis, a in primary care practices. The diferential diagnosis detailed history and physical examination remain crucial in the evaluation is extensive, thus making the diagnostic process of polyarticular symptoms. The vast diferential for polyarticular pain can difcult. A comprehensive history and physical exam be greatly narrowed using a thorough history. can help point towards the more likely etiology of the complaint. The physician must frst ensure that there are no symptoms pointing towards a more serious Emergencies diagnosis, which may require urgent management or During the initial evaluation, the physician must frst exclude any life- referral. -
Arthritis and Joint Pain
Fact Sheet News from the IBD Help Center ARTHRITIS AND JOINT PAIN Arthritis, or inflammation (pain with swelling) of the joints, is the most common extraintestinal complication of IBD. It may affect as many as 30% of people with Crohn’s disease or ulcerative colitis. Although arthritis is typically associated with advancing age, in IBD it often strikes younger patients as well. In addition to joint pain, arthritis also causes swelling of the joints and a reduction in flexibility. It is important to point out that people with arthritis may experience arthralgia, but many people with arthralgia may not have arthritis. Types of Arthritis • Peripheral Arthritis. Peripheral arthritis usually affects the large joints of the arms and legs, including the elbows, wrists, knees, and ankles. The discomfort may be “migratory,” moving from one joint to another. If left untreated, the pain may last from a few days to several weeks. Peripheral arthritis tends to be more common among people who have ulcerative colitis or Crohn’s disease of the colon. The level of inflammation in the joints generally mirrors the extent of inflammation in the colon. Although no specific test can make an absolute diagnosis, various diagnostic methods—including analysis of joint fluid, blood tests, and X-rays—are used to rule out other causes of joint pain. Fortunately, IBD-related peripheral arthritis usually does not cause any lasting damage and treatment of the underlying IBD typically results in improvement in the joint discomfort. • Axial Arthritis. Also known as spondylitis or spondyloarthropathy, axial arthritis produces pain and stiffness in the lower spine and sacroiliac joints (at the bottom of the back). -
T Helper Cell Infiltration in Osteoarthritis-Related Knee Pain
Journal of Clinical Medicine Article T Helper Cell Infiltration in Osteoarthritis-Related Knee Pain and Disability 1, 1, 1 1 Timo Albert Nees y , Nils Rosshirt y , Jiji Alexander Zhang , Hadrian Platzer , Reza Sorbi 1, Elena Tripel 1, Tobias Reiner 1, Tilman Walker 1, Marcus Schiltenwolf 1 , 2 2 1, 1, , Hanns-Martin Lorenz , Theresa Tretter , Babak Moradi z and Sébastien Hagmann * z 1 Clinic for Orthopedics and Trauma Surgery, Center for Orthopedics, Trauma Surgery and Spinal Cord Injury, Heidelberg University Hospital, Schlierbacher Landstr. 200a, 69118 Heidelberg, Germany; [email protected] (T.A.N.); [email protected] (N.R.); [email protected] (J.A.Z.); [email protected] (H.P.); [email protected] (R.S.); [email protected] (E.T.); [email protected] (T.R.); [email protected] (T.W.); [email protected] (M.S.); [email protected] (B.M.) 2 Department of Internal Medicine V, Division of Rheumatology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany; [email protected] (H.-M.L.); [email protected] (T.T.) * Correspondence: [email protected]; Tel.: +49-622-1562-6289; Fax: +49-622-1562-6348 These authors contributed equally to this study. y These authors share senior authorship. z Received: 16 June 2020; Accepted: 23 July 2020; Published: 29 July 2020 Abstract: Despite the growing body of literature demonstrating a crucial role of T helper cell (Th) responses in the pathogenesis of osteoarthritis (OA), only few clinical studies have assessed interactions between Th cells and OA—related symptoms. -
Treatment of Taxane Acute Pain Syndrome (TAPS) in Cancer Patients Receiving Taxane-Based Chemotherapy—A Systematic Review
Support Care Cancer (2016) 24:1583–1594 DOI 10.1007/s00520-015-2941-0 ORIGINAL ARTICLE Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy—a systematic review Ricardo Fernandes1 & Sasha Mazzarello2 & Habeeb Majeed3 & Stephanie Smith 2 & Risa Shorr4 & Brian Hutton5 & Mohammed FK Ibrahim1 & Carmel Jacobs1 & Michael Ong1 & Mark Clemons1,2,6 Received: 21 May 2015 /Accepted: 3 September 2015 /Published online: 19 September 2015 # Springer-Verlag Berlin Heidelberg 2015 Abstract randomized open-label trials 76 patients), and one was a ret- Background Taxane acute pain syndrome (TAPS) is charac- rospective study (10 patients). The agents investigated includ- terized by myalgias and arthralgias starting 1–3 days and last- ed gabapentin, amifostine, glutathione, and glutamine. Study ing 5–7 days after taxane-based chemotherapy. Despite nega- sizes ranged from 10 to 185 patients. Given the heterogeneity tively impacting patient’s quality of life, little is known about of study designs, a narrative synthesis of results was per- the optimal TAPS management. A systematic review of treat- formed. Neither glutathione (QoL, p = 0.30, no 95 % CI re- ment strategies for TAPS across all tumor sites was performed. ported) nor glutamine (mean improvement in average pain Methods Embase, Ovid MEDLINE(R), and the Cochrane was 0.8 in both treatment arms, p = 0.84, no 95 % CI reported) Central Register of Controlled Trials were searched from were superior to placebo. Response to amifostine (pain re- 1946 to October 2014 for trials reporting the effectiveness of sponse) and gabapentin (reduction in taxane-induced arthral- different treatments of TAPS in cancer patients receiving gias and myalgias) was 36 % (95 % CI, 16–61 %) and 90 % taxane-based chemotherapy. -
Therapeutic Optimization of Aromatase Inhibitor–Associated Arthralgia
Review Therapeutic optimization of aromatase inhibitor–associated arthralgia: etiology, onset, resolution, and symptom management in early breast cancer Cheryl Jones, MD,1 James Gilmore, PharmD,1 Mansoor Saleh, MD,1 Bruce Feinberg, DO,1 Michelle Kissner, RPh, PharmD,2 and Stacey J. Simmons, MD2 1Georgia Cancer Specialists, Macon, GA; 2Pfizer Inc., New York, NY Third-generation aromatase inhibitors (AIs) used in the treatment of hormone-responsive breast cancer are associated with arthralgia, which is the most common reason for treatment discontinuation. This review characterizes the observed arthralgia and describes its variable definitions in key clinical trials; its typical onset and duration; symptom management strategies; and symptom resolution. The symptomatic manifestations of AI-associated arthralgia are highly variable, with typical onset occurring 2-6 months after treatment initiation. Aromatase inhibitor-associated arthralgia is most often bilateral and symmetrical, involving hands and wrists. Other common locations include knees, hips, lower back, shoulders, and feet. To improve standardization of care as well as patient quality of life, we propose a diagnostic algorithm for the management of patients who receive AIs and who develop arthralgia or worsening symptoms from preexisting joint pain. We conclude that although arthralgia is often associated with AI therapy, prompt diagnosis and management of musculoskeletal symptoms may ensure continued AI treatment and improve quality of life. he use of third-generation aromatase in- -
Joint Pain and Sjögren’S Syndrome
Joint Pain and Sjögren’s Syndrome Alan N. Baer, MD, FACP Alan N. Baer, MD, FACP Associate Professor of Medicine Division of Rheumatology Johns Hopkins University School of Medicine Director, Jerome Greene Sjogren's Syndrome Clinic 5200 Eastern Avenue Mason F. Lord Bldg. Center Tower Suite 4100, Room 413 Baltimore MD 21224 Phone (410) 550-1887 Fax (410) 550-6255 In 1930, Henrik Sjögren, a Swedish ophthalmologist, examined a woman with rheumatoid arthritis who had extreme dryness of her eyes and mouth and filamentary keratitis, an eye condition related to her lack of tears (1). He became fascinated by this unusual debilitating condition and subsequently evaluated 18 additional women with the same combination of findings. He described this new syndrome as “keratoconjunctivitis sicca” in his postdoctoral thesis. Thirteen of the 19 women had chronic inflammatory arthritis. We would now classify these 13 women as having secondary Sjögren’s syndrome (SS), occurring in the context of rheumatoid arthritis. However, joint pain constitutes one of the most common symptoms of the primary form of SS, defined as SS occurring in the absence of an underlying rheumatic disease. In a recent survey of SS patients belonging to the French Sjögren’s Syndrome Society (Association Française du Gougerot-Sjögren et des Syndromes Secs), 81% reported significant joint and muscle pain (2). In this article, the joint manifestations of primary SS will be reviewed. A few definitions are needed for the reader. Although the term “arthritis” was originally applied to conditions causing joint inflammation, it now includes disorders in which the joint has become damaged by degenerative, metabolic, or traumatic processes. -
Adult-Onset Still's Disease As the First Manifestation of Cerebral Infarction: a Case Report
02 Brain Neurorehabil. 2018 Sep;11(2):e13 https://doi.org/10.12786/bn.2018.11.e13 pISSN 1976-8753·eISSN 2383-9910 Brain & NeuroRehabilitation Case Report Adult-onset Still's Disease as the First Manifestation of Cerebral Infarction: a Case Report Jong Kyoung Choi, Yu Jin Seo, Dae Yul Kim Received: Feb 27, 2018 HIGHLIGHTS Revised: Jun 19, 2018 Accepted: Jun 29, 2018 • Adult-onset Still’s disease (AOSD) is a rare systemic febrile disorder of unknown etiology. Correspondence to • Cerebral infarction as the first manifestation of AOSD has not been reported. DaeYul Kim • This case report is the first report cerebral infarction as the first manifestation of AOSD in Department of Rehabilitation Medicine, Asan a young stroke patient during rehabilitation period. Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. E-mail: [email protected] Copyright © 2018. Korea Society for Neurorehabilitation i 02 Brain Neurorehabil. 2018 Sep;11(2):e13 https://doi.org/10.12786/bn.2018.11.e13 pISSN 1976-8753·eISSN 2383-9910 Brain & NeuroRehabilitation Case Report Adult-onset Still's Disease as the First Manifestation of Cerebral Infarction: a Case Report Jong Kyoung Choi ,1,* Yu Jin Seo ,2 Dae Yul Kim 2 1Department of Rehabilitation Medicine, Dong-Eui Medical Center, Busan, Korea 2Department of Rehabilitation Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Received: Feb 27, 2018 ABSTRACT Revised: Jun 19, 2018 Accepted: Jun 29, 2018 Adult-onset Still's disease (AOSD) is a rare systemic febrile disorder of unknown etiology. -
Cervical Spine Dysfunction Signs and Symptoms in Individuals with Temporomandibular Disorder
Original Article Cervical spine dysfunction signs and symptoms in Artigo Original individuals with temporomandibular disorder Priscila Weber1 Frequência de sinais e sintomas de disfunção cervical em Eliane Castilhos Rodrigues Corrêa2 Fabiana dos Santos Ferreira1 indivíduos com disfunção temporomandibular Juliana Corrêa Soares1 Geovana de Paula Bolzan3 Ana Maria Toniolo da Silva2 Keywords ABSTRACT Facial pain Purpose: To study the frequency of cervical spine dysfunction (CCD) signs and symptoms in subjects with Neck pain and without temporomandibular disorder (TMD) and to assess the craniocervical posture influence on TMD Craniomandibular disorders and CCD coexistence. Methods: Participants were 71 women (19 to 35 years), assessed about TMD presence; Posture 34 constituted the TMD group (G1) and 37 comprised the group without TMD (G2). The CCD was evaluated Cephalometry through the Craniocervical Dysfunction Index and the Cervical Mobility Index. Subjects were also questioned Signs and symptoms about cervical pain. Craniocervical posture was assessed by cephalometric analysis. Results: There was no difference in the craniocervical posture between groups. G2 presented more mild CCD frequency and less moderate and severe CCD frequency (p=0.01). G1 presented higher percentage of pain during movements (p=0.03) and pain during cervical muscles palpation (p=0.01) compared to G2. Most of the TMD patients (88.24%) related cervical pain with significant difference when compared to G2 (p=0.00). Conclusion: Cra- niocervical posture assessment showed no difference between groups, suggesting that postural alterations could be more related to the CCD. Presence of TMD resulted in higher frequency of cervical pain symptom. Thus the coexistence of CCD and TMD signs and symptoms appear to be more related to the common innervations of the trigeminocervical complex and hyperalgesia of the TMD patients than to craniocervical posture deviations.